Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

Terminated

• Conditions: Pulmonary Hypertension; Systemic Sclerosis; Pulmonary Arterial Hypertension

• Registration Number: NCT00706082
• Lead Sponsor: Actelion

Brief Summary

A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-06-25
• Study First Submitted QC: 2008-06-26
• Study First Posted: 2008-06-27
• Study Start: 2008-10
• Primary Completion: 2011-11
• Study Completion: 2012-03
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-21
• Last Update Posted: 2012-06-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 490

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary arterial hypertension (PAH) confirmed by right heart catheterization (RHC)	Baseline and 3-year follow-up

Secondary Outcome Measures

Name	Time	Method
Pulmonary hypertension (PH) confirmed by right heart catheterization (RHC)	Baseline and 3-year follow-up

Trial Locations

Locations (82)

University of Alabama at Birmingham, 311 THT; 🇺🇸 Birmingham, Alabama, United States

UCLA Division of Rheumatology; 🇺🇸 Los Angeles, California, United States

Harbor UCLA Medical Center; 🇺🇸 Torrance, California, United States

University of CT; 🇺🇸 Farmington, Connecticut, United States

Department of Rheumatology; 🇺🇸 Washington, District of Columbia, United States

University of Florida; 🇺🇸 Jacksonville, Florida, United States

Rheumatology, MC 733, The University of Illinois-Chicago; 🇺🇸 Chicago, Illinois, United States

John Hopkins, Division of Rheumatology; 🇺🇸 Baltimore, Maryland, United States

Boston University School of Medicine; 🇺🇸 Boston, Massachusetts, United States

University of Michigan Scleroderma Program; 🇺🇸 Ann Arbor, Michigan, United States

Scroll for more (72 remaining)